Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
AssigneeAbbott Laboratories
InventorsJoMay Chow, Steven R. Davis, Rachael Buck, Geralyn O. Duska-McEwen, Hawley K. Linke
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Claims16
A shelf stable synthetic formula for improving the feeding tolerance of an infant, toddler, or child, the synthetic formula comprising:
- from about 0.04 mg/mL to about 20 mg/mL of a human milk oligosaccharide blend consisting of 2′-fucosyllactose, 3-fucosyllactose, 3′-sialyllactose, 6′-sialyllactose, and at least one of lacto-N-tetraose and lacto-N-neotetraose, wherein the oligosaccharide blend comprises 2′-fucosyllactose, in a concentration of from 0.01 mg/mL to 10 mg/mL, and 6′-sialyllactose, in a concentration of from 0.01 to 10 mg/mL;
- from about 0.001 g/L to about 1 g/L of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid, wherein the ratio of docosahexaenoic acid to arachidonic acid is from about 1:4 to about 1:2;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising lutein, lycopene, beta-carotene, or a combination thereof;
- from about 42 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates;
- and
- wherein the synthetic formula is shelf stable for at least 3 months.
A method of improving the intestinal barrier integrity of an infant, toddler, or child, the method comprising:
- identifying an infant toddler or child having impaired intestinal barrier integrity and
- administering to the infant toddler or child a synthetic formula comprising:
- from about 0.02 mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein the oligosaccharide blend comprises a first human milk oligosaccharide, 2′-fucosyllactose, in a concentration of from 0.01 mg/mL to 10 mg/mL, and a second human milk oligosaccharide, 6′-sialyllactose, in a concentration of from 0.01 to 10 mg/mL;
- a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid, wherein the long chain polyunsaturated fatty acid component is present in an amount of less than 3% of a total fat content of the synthetic formula;
- from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising lutein, lycopene, beta-carotene, or a combination thereof;
- from about 42 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
- wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates.
Dependencies are inferred from the claim text.